Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
23,630 total articles
Terra Innovatum announced the appointment of three new independent directors with expertise in nuclear safety, engineering, and financial leadership to support its transition from development to commercialization of the SOLO™ Micro-Modular Reactor. The company is also establishing a Technology, Safety and Licensing Committee to oversee critical tec…
Viasat Inc., through its subsidiary Inmarsat Government, has been awarded a $42 million initial task order as part of a seven-year, up to $307 million indefinite delivery/indefinite quantity contract to provide global satellite communication services to the U.S. Marine Corps. The contract leverages Viasat's multi-orbit satellite network and flexibl…
Aduro Clean Technologies Inc. reported successful results from successive 75-hour campaigns at its Next Generation Process Pilot Plant, achieving condensable hydrocarbon yields from 88.8% to 90.8% across different polypropylene and polyethylene feed blends. The company highlighted improved process control, consistent product quality, and the use of…
Paychex has introduced WISE Hire, an AI-native recruiting platform integrated with its existing HCM offerings, designed to help businesses source and hire qualified candidates up to 4 times faster. Combining AI agents for sourcing, screening, and hiring coaching with human oversight, the solution maintains employer control while automating routine …
Magnite (NASDAQ: MGNI) has been named the primary video ad server and programmatic technology provider for HP TV+, the ad-supported streaming service targeted at personal computer users. This partnership enables HP TV+ to leverage Magnite's omnichannel suite to offer advertisers enhanced access to programmatic demand across HP TV+ banner and video …
BIO-key International announces its Passkey:YOU authentication solution has achieved Full Certification from the FIDO Alliance, validating its compliance with phishing-resistant passwordless authentication standards. This certification enables Passkey:YOU to integrate seamlessly with major identity platforms and supports biometric authentication wi…
Clearmind Medicine Inc., a clinical-stage biopharmaceutical company listed on Nasdaq, announced the publication of three U.S. patent applications for novel combinations of LSD, ketamine, and ibogaine with N-acylethanolamines, including PEA. These patents potentially cover therapeutic uses for depression, PTSD, pain, and substance use disorders, exp…
3 E Network Technology Group Limited announces that its Nordic subsidiary, Aurora Core Technology Oy, has entered the implementation phase for a multi-megawatt green energy AI data center project in Finland. The subsidiary is managing procurement, grid interconnection, environmental approvals, municipal waste heat monetization negotiations, local e…
BridgeBio Pharma announced results from a peer-reviewed real-world study demonstrating that Acoramidis significantly reduces the risk of clinical worsening events in transthyretin amyloid cardiomyopathy (ATTR-CM) patients compared to Tafamidis. The study showed a 34% reduction in composite risk of worsening, including heart failure hospitalization …
VEON Ltd., a global digital operator listed on NASDAQ, announced an increased share buyback program worth approximately $200 million to repurchase 3.9% of its outstanding shares. The company plans to cancel all repurchased shares, reinforcing its capital allocation discipline and commitment to long-term value creation. This program represents a sig…
Winnebago Industries announced it will release its fourth quarter and full fiscal 2026 financial results on October 21, 2026, before the NYSE opens. A conference call will follow, hosted by its CEO and CFO, accessible via the company's investor relations website. The company is a leading North American manufacturer of outdoor recreation products in…
Artelo Biosciences announced the filing of a new provisional patent application for ART27.13, a dual cannabinoid receptor agonist, targeting obesity treatment both as monotherapy and combined with GLP-1 receptor agonists like semaglutide. Nonclinical studies demonstrated up to 40% weight loss in obese mice when ART27.13 was combined with semaglutid…
Wave Life Sciences initiated a Phase 2a clinical trial evaluating its investigational RNA medicine WVE-007 in combination with tirzepatide for obesity treatment. Preclinical and emerging data indicate that WVE-007, utilizing GalNAc-siRNA technology, induces fat loss without muscle loss and could enhance weight loss beyond GLP-1 therapies alone. The…
Beneficient has announced a comprehensive strategy to eliminate the fraudulent HCLP debt of approximately $130 million and convert the former CEO Brad Heppner's substantial equity interests valued around $850 million into common stock, while terminating all related agreements. This follows Heppner's conviction for securities and wire fraud. The res…
Nexentis Technologies Inc., through its wholly-owned subsidiary MitoCareX Bio Ltd., is evaluating additional commercially available approaches to obtain proteins for its in-vitro drug discovery research. This initiative aims to broaden research capabilities, increase flexibility, and support future discovery programs. The evaluation is in early sta…
Biomea Fusion, a clinical-stage company focused on diabetes and obesity treatments, has terminated its proposed public offering of securities due to current market conditions deemed unfavorable for stockholders. No shares were sold, and the decision reflects management's commitment to protecting shareholder interests amid volatile markets.
Psyence Biomedical Ltd. announced a strategic investment of up to $5 million in PsyLabs alongside a reciprocal $9 million share exchange aimed at supporting the development and manufacturing capabilities of pharmaceutical-grade ibogaine. The company established Texas Ibogaine Research Corporation to facilitate clinical and regulatory activities for…
Auddia Inc. announces the appointment of former U.S. Secretary of Defense Mark T. Esper to the board of LT350, a subsidiary of the pending merger that would form McCarthy Finney Inc. Esper's expertise enhances LT350’s positioning as a national security-aligned AI-edge computing company targeting commercial and defense markets. The merger, if comple…
Immunovant announced topline results from its proof-of-concept study evaluating IMVT-1402 in cutaneous lupus erythematosus (CLE). The study did not achieve statistical significance on the primary endpoint at 12 weeks. Despite positive trends in some secondary endpoints and a favorable safety profile, the company will discontinue development of IMVT…
Seer, Inc., a US-listed proteomics company, announced that Nanyang Technological University researchers will present early findings from the PRECISE-SG100K study at the 2026 HUPO World Congress. The study leverages Seer's Proteograph Product Suite combined with advanced mass spectrometry to deeply analyze the circulating proteome of 10,000 particip…
GXO Logistics has begun pilot deployments of a new Labor Management System (LMS) across major regions including North America and Europe. The LMS aims to standardize labor management globally, enhance workforce planning, improve operational efficiencies, and support the company's growth and profitability goals. Full-scale rollout is planned for 202…
Avalo Therapeutics announced its participation in the upcoming European Academy of Dermatology and Venereology (EADV) 2026 Congress with a late-breaker oral presentation and poster showcasing the efficacy and safety data from its Phase 2 placebo-controlled LOTUS trial of abdakibart in treating moderate to severe hidradenitis suppurativa. The data p…
Oruka Therapeutics announced positive Week 28 data from the EVERLAST-A Phase 2a trial evaluating ORKA-001 in moderate-to-severe plaque psoriasis. Results show increasing skin clearance rates (PASI 100 up to 71.4%) months after the last dose at Week 4, with a strong safety and tolerability profile consistent with the IL-23p19 monoclonal antibody cla…
Roivant announced that Immunovant's proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus (CLE) failed to achieve statistical significance on its primary efficacy endpoint. Despite positive trends on secondary measures and a favorable safety profile, development for this indication will cease. Immunovant remains focused on advancing …
AC Immune SA reported positive safety and immunogenicity data through week 100 in Part 1 of its VacSYn Phase 2 trial of ACI-7104 in early-stage Parkinson's disease patients. All primary endpoints—safety, tolerability, and immunogenicity—were met, with 100% of patients developing antibodies against the target. The trial showed strong antibody penetr…
